Citations (5)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Abdelmoujoud Faris, Ibrahim M. Ibrahim, Radwan Alnajjar, Hanine Hadni, Mashooq Ahmad Bhat, Muhammad Yaseen, Souvik Chakraborty, Nada Alsakhen, Israa M. Shamkh, Fazal Mabood, Ahmed M. Naglah, Ihsan Ullah, Noha Ziedan & Menana Elhallaoui. QSAR-driven screening uncovers and designs novel pyrimidine-4,6-diamine derivatives as potent JAK3 inhibitors. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-30.
Read now
Read now
Abdelmoujoud Faris, Ivana Cacciatore, Ibrahim M. Ibrahim, Mohammed H. AL Mughram, Hanine Hadni, Kamal Tabti & Menana Elhallaoui. In silico computational drug discovery: a Monte Carlo approach for developing a novel JAK3 inhibitors. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-23.
Read now
Read now
Articles from other publishers (3)
Jian Liu, Rohit Solan, Robert Wolk, Anna Plotka, Melissa T. O'Gorman, Jennifer A. Winton, Julia Kaplan & Vivek S. Purohit. (2023) Evaluation of the effect of ritlecitinib on the pharmacokinetics of caffeine in healthy participants. British Journal of Clinical Pharmacology.
Crossref
Crossref
Yihao Li, Dan Meng, Jiali Xie, Ruoyu Li, Zifan Wang, Jinlong Li, Lin Mou, Xinhao Deng & Ping Deng. (2022) Design of Rational JAK3 Inhibitors Based on the Parent Core Structure of 1,7-Dihydro-Dipyrrolo [2,3-b:3′,2′-e] Pyridine. International Journal of Molecular Sciences 23:10, pages 5437.
Crossref
Crossref
H.A. Ramírez‐Marín & A. Tosti. (2022) Assessing the efficacy of selective JAK inhibitors for alopecia areata with a patient‐centered approach. Journal of the European Academy of Dermatology and Venereology 36:4, pages 494-495.
Crossref
Crossref